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Despite a large volume of evidence supporting its cardioprotective properties and its other
numerous established health beneﬁts, physical activity is not a serious prescription option for the
primary prevention of cardiovascular disease. On the other hand, health services increasingly focus
on pharmacological prevention without considering properly the long-term consequences of
medication. Ethical and feasibility considerations suggest that evidence on the protective value of
physical activity may need to be evaluated using criteria different from those applying to phar-
macological trials. The collateral health beneﬁts of physical activity prescription support its use as
standard option in preventive health care.
Cardiovascular disease (CVD) is the main
causeofdeathindevelopedcountriesandin
the UK alone claims over 200000 lives per
year. CVD is aetiologically complex and
multifactorial. The majority of CVD risk
factors are largely modiﬁable (eg, physical
inactivity, smoking, poor diet, excessive
alcohol consumption, stress), while others
are less modiﬁable (eg, psychosocial
factors) or unmodiﬁable (eg, genetic
predispositions and age/sex). Complex and
often poorly understood combinations of
these risk factors result in disturbances to
human physiology and biology, leading to
the development of disease signs, such as
obesity and type 2 diabetes, hypertension,
dyslipidaemia and atherosclerosis. The
consequence of these disturbances is
expression of fatal or non-fatal CVD.
Physical inactivity and low cardiorespi-
ratory ﬁtness, its direct consequence, have
been shown to be some of the largest
aetiological contributors (along with
smoking and diet) with hundreds of
studies showing strong independent links
with increased incidence of CVD and
overall mortality.
1 This is not reﬂected by
current medical practice. Instead, the bio-
logical surrogate outcomes of poor life-
styles and stressful environments (eg,
hypertension, obesity and raised blood
cholesterol), are given “causal” factor
status. With the exception of smoking, the
actual behavioural causes of CVD are often
called “predisposing” risk factors “.whose
inﬂuence on CVD is due entirely to inten-
siﬁcation of the causal factors (e.g. blood
pressure, cholesterol, glucose)”.
2 Such
logic has resulted in a disproportionate
focus on pharmacology for CVD preven-
tion, mainly lipid and blood pressure-
lowering medications. For example, in the
case of statins, the evidence supporting
their prescription for primary CVD preven-
tion is highly controversial.
3 Nevertheless,
prescribing pressure comes from govern-
ment health policy and in countries such as
the United Kingdom general practitioners
are incentivised to meet their contracts by
prescribing to reduce cholesterol and blood
pressure. While physical activity counsel-
ling is not a serious option (if an option at
all), it is alarming that there are calls to
even medicate whole populations regard-
less of baseline biological risk level.
4
Butwhatarethereasonsfortheapparent
neglectofphysicalactivity? First, although
physical activity increases even in later life
have been shown to decrease mortality risk
as much as smoking cessation,
5 there is
limited randomised control trial (RCT)
evidence showing that improvements in
physical activity will lead to reduced
mortality. In medical evidence hierarchy,
RCTs are the only design that can support
direct causal inferences but it is neither
feasible nor ethical to instruct the control
group of such a trial to be inactive for long
periods of time. Thus, we may never be
able to have the level of medical evidence
required to make physical activity the ﬁrst
preventive option.
Second, there is a widespread belief
among clinicians that people cannot
change physical activity habits
6 but we are
not aware of any country where
a substantial investment has been made to
research which interventions might work
in a primary care setting. For example, in
the UK National Health Service there have
only been a handful of physical activity-
promoting initiatives in the past decade,
all of which were of small scale and with
minimal ﬁnancial commitment. This is
not justiﬁed as there is evidence showing
thatevenbriefconsultations(3e10 minutes)
or simple pedometer-based programmes
delivered through health professionals can
lead to substantial increases in patients’
activity levels (by w30%).
7 Conversely,
adherence to medication is very low as
only one in six patients takes their medi-
cation as prescribed
8 and approximately
half of patients are sufﬁciently concordant
in order to attain therapeutic objectives,
yet medication is usually prescribed as
a ﬁrst option. The actual public health
beneﬁts of preventive CVD medication
may be far lower than the, often ques-
tionable,
3 RCT evidence upon which
current practices are based. Worryingly,
many general practitioners are not aware
of the importance of physical activity
9 and
there are clear educational needs to be
addressed. In addition, the average patient
consultation lasts 9 minutes in the UK and
the power to retain control over the
consultation and prescribe a “pill for all
ills” lies with the doctor. Unfortunately it
is often far easier to issue a prescription to
reduce blood pressure, cholesterol or body
mass index targets than to fully address
and follow up the multiple beneﬁts and
methods for improving a lifetime of risky
lifestyle habits.
Third, the economies surrounding phar-
maceutical companies have the power to
fundandpubliciseresearchthatsupportsthe
effectiveness of their products (and hence
inﬂuence policy) and it is a well-known
secret that pharmaceutical companies
promotetheiragendasrelentlesslybymeans
of sponsorship and gifts among healthcare
professionals (and hence inﬂuence prac-
tice).
10 On the other hand, research on
physical activity is sparingly funded.
Fourth, the frequently evidenced failure
of the physical activity groups to meet the
primary endpoint in trials reinforces views
against physical activity.
11 Again, it is
unfair to judge a physical activity trial
using the standard medical evidence
criteria that invariably are concerned with
dichotomous outcomes (success/failure).
Because of the multiple beneﬁts of
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different level of beneﬁt any physical
activity intervention can have, physical
activity trials should be evaluated using
multiple endpoints in a continuous
fashion (very beneﬁcial, beneﬁcial, moder-
ately beneﬁcial, not beneﬁcial, moderately
harmful, etc). The dichotomous outcome
research model is more appropriate for
drug trials, with very limited or no collat-
eral beneﬁts and targeted action. All drugs
have undesirable, known or unknown,
side-effects that are often alleviated using
other drugs that may in turn have more
side-effects, making it nearly impossible to
accurately track how medication affects
quality of life in the long term. Side-effects
are usually evaluated by indices of
mortality and morbidity over a short
period of time with little regard to how
lifetime medication (like statins and b-
blockers that are typically used for CVD
prevention) may affect quality of life. On
the other hand, the collateral beneﬁts of
regular physical activity are numerous and
evidence suggesting new beneﬁts is
constantly emerging. Further, the degree of
health beneﬁts physical activity offers is
likely to be greater than what the evidence
suggests for reasons relating to how
evidence has been produced: such evidence
comes primarily from prospective studies
with a single self-reported exposure
assessment at baseline. True effect sizes are
bound to be larger than what evidence
suggest for at least two reasons: (a) the
large measurement error associated with
self-reporting weakens the strength of the
associations between exposure and
outcomes, and (b) unmeasured reductions
in physical activity with age over the
follow-up period that may subsequently
dilute considerably effect sizes.
Finally, we speculate that relying
merely on medication for CVD prevention
may give a false sense of “I’m doing my bit
for my health” and responsibility for
health is transferred from the patient to
the doctor via their concordance with
medication. It has been shown that CVD-
free individuals who are on CVD medica-
tion have lower adjusted odds to meeting
the physical activity recommendations
compared to those who are unmedicated.
12
There is no doubt that CVD medication
such as lipid lowering and blood pressure
lowering can save lives but their estab-
lishment as a ﬁrst-and-only primary
preventive choice is scientiﬁcally unjusti-
ﬁed and perhaps socially irresponsible.
Developing and prescribing such drugs
have taken large private and public
investments and effort. It is high time the
same investment is made in ﬁnding
successful ways to facilitate and support
active lifestyles for all. This not only will
minimise the burden of cardiovascular and
other chronic disease but it will also help
people to live happier and fuller lives. As
Hippocrates said, “if we could give every
individual the right amount of nourish-
ment and exercise, not too little and not
too much, we would have found the safest
way to health” and “walking is the man’s
best medicine”. Two thousand four
hundred years later it is not too late to put
these principles into practice.
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